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Abstrct 
An experimental model of immunotherapy for intracranially transplanted mouse l戸nphoma
is described. In Winn type neutralization assays in the brain, slight e伍ciencyof immune 
lymphocytes was observed, on the other hand‘the nude mice with intracranially transplanted 
mouse lymphoma were successfully treated by a single intravenous transfer of immune l戸npho-
りrtes. This effect was totally eliminated by the treatment of lymphocytes with anti Thy-1 anti-
body and complement before transfer, whereas the passage through a nylon-wool column had no 
effect on tumor rejection. By the treatment with anti Lyt antibodies and complement, Lyt-2+ 
cytotoxic T lymphocytes appeared to be responsible for the effector T-cell subpopulations in 
a systemic transfer study. The effectiveness of tumor-specific cytotoxic T-cell lines, which were 
established and maintained without added IL-2 and mainly consisted of Lyt-2+ T-cells, was 
demonstrated not only in the Winn neutralization test in the brain, but also in the adoptive 
transfer study. On the other hand, the noncytotoxic cell line that entirely consisted of Lyt-1 + 
T-cells had no such effect. 
In conclusion, the rejection of mouse l戸nphomain athymic nude mice was considered to be 
mediated by Lyt-2+ cytotoxic T lymphocytes. 
Introduction 
In several syngeneic animal tumor models, the adoptive transfer of tumor sensitized lympho-
cytes can cause total regression of established tumors and permanently cure the animals of 
disease2，州. The immunity to allografts or syngeneic tumor cells has been shown to be mediated 
mainly by T cels, referred to as cytotoxic T lymphocyte (CTL）判＞. Passiv巴transferof immunity 
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for the treatment of cancer in animals and m羽 hasbeen attempted45>. Functional subclasses of 
T lymphocytes on Lyt antigens have been extensively studied and CTLs have been found to ex-
press the Lyt-2+ antigenもあ37>. CTL had b巴enconsidered to be the main ef1巴ctorcel population 
in both allograft and syngene1c tumor rejection, becaus巴ofits capacity to kil tumor cels directly 
in vitro, and the generation of thes巴 cellsduring rejection6>. Therefore, the activation and 
expansion of the CTL population has been attempted 15• 27> and numerous CTL clones hav巴been
successfully established using interleukin 2(IL-2)11·12•16•22•40,so,s2>. However, contraηr to our 
expectations, there hav巴 beenfew reports indicatives that IL-2-dependent CTL clones are 
efective in protecting against the allo-or s戸igen巴ictumor growth in in vivo systemic transfer 
studies11，問. On the other hand, recent observations have demonstrated that allografts34,as>, 
or syngeneic tumors19,21,2a> are rejected by systemic transfer of Lyt-i+ cels, but not by Lyt・2+
CTL populations. Therefore, the determination of an effector T lymphocyte subpopulation is 
essential to promote adoptiv巴immunotherapyagainst malignancies in humans. 
Although several experimental models have been reported dealing with adoptive immuno-
therapy to intraperitoneally7•s,i7,is,2a> or subcutan巴ously1s,19,21,29,a9,41,4s>transplanted tumors, 
few studies have dealt with the intracranial tumor model叫 4,40,s2>probably because of the 
immunological pecu日alityof the central nervous system (CNS)1>. 
Recently, the authors demonstrated a slightly low but detectable immunological response in 
the brain using transplanted mouse lymphoma in the comparative experiments with extracranial 
immunological responsesao>. In the present study experimental immunotherapy to intracranially 
transplanted mouse lymphoma is described, and th巴importanceof CTL as the effector cells in 
tumor rejection is also demonstrated. 
Materials and Methods 
Mice: Breeding pairs of nude mice and their h巴terozygouslit巴rmateswith BALB/c 
and C57BL/6 backgrounds respectively, were originally purchased from Clea Japan Inc., Tokyo, 
Japan and nude or their heterozygous (BALB/c×C57BL/6)F1 mice, denoted CB6F1 or CB6F1-
nu/nu, were raised and maintained under specific pathogen free conditions in the Facilities of 
Experimental Animals, Faculty of Medicine, Kyoto University. Male and female mice were 
used between 6 and 12 weeks of age. 
Tumors: RL61, together with RL古6and RL平9(kindly provided by Dr. Nakayama, 
The Center of Adult Disease, Osaka, Japan), is a radiation-induced leukemic cel line of BALB/c 
origin which has been maintained in BALB/c mouse in its ascitic form. Other tumors used in 
the present study were P815 (methylcholanthrene-induced mastocytoma of DBA/2 origin), and 
EL-4 (dimethylbenzanthrecene induced leukemia of C57BL/6 origin). P815 and EL-4 cells 
were maintained in the corresponding syngeneic strain of mice in their ascitic forms. 
In Vivo Immunization: The procedures with RL古1hav巴beenpreviously described 3>. 
In brief, 6 to 8-wk-old male and female CB6F日m/+ mice received intradermal (ID) injections 
on their backs with 5×105 RL古1cells in a volume of 0.1 ml Hanks’balanced salt solution 
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(HBSS). The tumor grew to 5-10 mm indiameter in about 2 weeks and then regressed spon-
taneously in the following 4 weeks. This is in accordance with the previous observation38J. 
After complete regression of the tumor, the mice were boosted three times with increasing numbers 
of viable RL 6 1 cells up to 5×101 cells at an interval of two weeks. Three weeks after the last 
immunization, spleen cells were used as donors of responding cells in mixed lymphocyte司tumor
cel culture (ML TC), or as effector immune spleen cells for the study either of Winn-type neutrali-
zation assay or for adoptive transfer studies. 
Intracranial Transplantation of Tumors: RL古1cells (104) suspended in a volume of 
0.01 ml of HBSS were injected under sterile conditions through the right frontal cranial bone to a 
depth of 2 mm with a 0.05 ml glass microsyringe (Hamilton Co., Reno, NA) and a 27-gauge 
Y AOI needle28l. 
Preparation of E宜ectorCells: Spleens of CB6F1-nu／十micethat had been immunized 
against RL古1in vivo were aseptically removed, pooled and crushed gently with a loose-fitting 
glass homogenizer in HBSS. After removing large cel clumps and debris with cotton wool, 
the spleen cells obtained were washed three times and resuspended in HBSS. 
Details for generation and maintenance of cytotoxic and noncytotoxic cel lines, CTLL-D4 
and D4f, have been previously described33l. Briefly, MLTC was performed between the RL古1・
immune CB6F 1-nu/ + spleen cells as responders and 10,000 R-irradiated RL 61 cells as stimu-
lators in 2 ml of complete medium (CM) in 24-well multidish culture plates (Coming Glass 
Works, Science Products Division, Coming, NY). CM used in this experiment was composed of 
RPMI・1640(Grand Island Biological Co., Grand Island, NY) supplemented with 10% FCS 
(Flow Laboratories, Inc., Rockvile, MD), 5×10-5 M 2-mercaptoethanol, 10 mM HEPES, 
100 U /ml penicilかiand 0.1 mg/ml streptomycin. The cultures were incubated for 5 days at 
37°C in a humid出edatmosphere of 5% C02 in air. After incubation, the cells were harvested, 
washed and then ~esuspended in RPMI・1640supplemented with 10% FCS and assayed for cyt＇か
toxic activity by chromium release assays7> An aliquot of ML TC cells was used further for 
the secondary in vitro micro-ML TC on the same day and this was prepared in CM to which 5% 
(vol/vol) IL-2 was added. Thus, each culture contained 5×102班LTC cells as responders, 
5×10s irradiated (2,000 R) CB6F1-nu/+ spleen cells as feeders and 5×104 irradiated (10,000 R) 
RL古lcells as stimulators in a final volume of 0.2 ml per well of a flat-bottomed 96-well micro-
culture plate (Corning Glass Works). Cytotoxic cell lines against RL古1derived from the 
secondary micro-ML TC were selected on day 14 after the initiation of culture, and transferred to 
and maintained in 2 ml cultures that contained 5×106 feeder cells and 5×10仁 1×10sstimulator 
cells in CM. After transferring the proliferating cells from microculture, no lL-2 was added to 
the culture. Aft巴rthe initial expansion, CTL lines wer巴passedafter 7 to 14 days by transferring 
1×106 ceJls to the well of a 24-well culture plate together with both feeder and stimulator cels. 
Among the CTL lines able to proliferate in culture, CTLL-D4 was chosen for its high proliferative 
response and specific cytotoxic activity against RL 6 1. A noncytotoxic cell line, D4f, was 
obtained by culturing CTLL-D4 only with the splenic feeder cels. D4f cells thus prepared 
co加pletelylost its cytotoxic activity against RL古1. Cytotoxic activity of CTLL-D4 and D4f 
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cels against RL古lmeasured by a 5・hrchromium release assay was about 50-60% and 0%, 
respectively, at the effector to target cel ratio of 1 : 1. CTLL-D4 cels consisted of mixed 
P叩ulationswith regard to Lyt phenotype expression; 15-25% Lyt-1+23-, 10 15% Lyt-1-23+ 
and 60-75% Lyt-1+23+ cels. D4f cells consisted entirely of Lyt-1+23-cels. 
Treatment of Lymphocytes: An anti Thy-1.2 monoclonal antibody (H0-13.4), origin-
aly supplied from the Cell Distribution C巴nter,Salk Institute of Health, San Diego, CA, was 
used for depletion of Thy-I+ cells at a 1/100 dilution. Anti Lyt・1.2and anti Lyt-2.2 mon-
oclonal antibodies supplied from Meiji Institute of Health Science, Tokyo, Japan, were used at 
a 1/50 dilution. Immune spleen cells were prepared as described above and adjusted to a con-
centration of 2×107 cells/ml in Medium-199 (GIBCO) containing the desired concentration of 
the antibody. Cells were incubated for 60 min at 4°C with intermittent agitation, and they were 
then centrifuged and resuspended with preselected nontoxic rabbit serum as complement (C) 
source for 30 min at 37°C with occasional shaking. After treatment, the cels were washed three 
times and resuspended at a desired concentration in HESS. 
IL・2: SD rat spleen cells (2.5×106) were incubated for 24 hrs at 37°C in 5% C02 in the 
presence of 5 μ.g/ml Concanavalin A (Con A). The resulting culture supernatants w巴reharvested, 
centrifuged and passed through 0.45 μ.m filters (Millipore Corp., Bedford, MA). One lot of the 
rat Con A supematants was selected and used for TCGF. 
Winn-type Neutralization Assay: The Winn勺rp巴neutralizationassay51> was carried 
out using CB6F1-nu/nu mice as recipients. The effector cels, prepared as de悶 ibedabove 
and adjusted to the desired concentration, were mixed with an equal volume of tumor cels 
(2×1Q6/ml). The mixture was injected intracranially in a volume of 0.01 ml as described 
above. The mice wihch survived for more than 60 days after inoculation were considered 
as cured. The control mice, intracranially injected with 0.01 ml HESS or effector cells only, 
also survived for more than 60 days after injection. 
In Vivo Assays of Adoptive Immunotherapy: CB6F1-nu/nu m悶 werealso used as 
the recipients in this assay. Various numbers of effector cells in 0.5 ml of sterile HESS were 
i附 avenouslytransferred into the tail vein of CB6F i-nu/nu mice, which had been inoculated 
with l×104 tumor cells intracranially 3 days earlier. The mice which survived for more than 
60 days after tumor inoculation were considered cured of tumor. The control mice, intravenously 
injected with 0.5 ml HESS or effector cells only, also survived for more than 60 days after 
iniection. 
Results 
IC Neutralization Assay: Injection of a mixture of either 5×104 (E/T=5 : 1)or 2×105 
(E/T=20 : 1)normal spleen cells with 1×104 RL古1cells into the IC site of CB6F i-nu/nu 
mice resulted in no effect on survival time compared with the injection of tumor cells alone (Fig. 1). 
Mixed-inoculation of immune spleen cells and tumor cells had a signi五canteffect on survival 
time (E/T=5 : 1 p<0.05, 20 : 1 p<0.02), however, no mouse was cured permanently. In this 
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Fi~. 1. Intracranial neutralization assay using spleen cels. CB6F 1-nu/nu mice 
were I吋ectedwith either l×104 RL古1cels （・hor admixtures of RL古l
and effector cels in a volume of 0.01 ml, respectively. E仔ectorcels are: 
normal CB6F1-nu/+ spleen cels E/T=20 : 1 （ム）； 5: 1 （企）； RL古1・
immune CB6F1-nu/+spleen cels E/T=20: 1 (0); 5 1 （・）. Each group 
consisted of eight to ten mice. 
T-cell line, CTLL-D4, had a neutralizing effect. The mice that received an admixture of CTLL-
D4 and RL舌1cells, at an E/T ratio of 20 : 1,were cured except for one mouse. This effect of 
CTLL-D4 is reduced in proportion to the decrease in the E/T ratio. On the other hand, the 
noncytotoxic cell line, D4f, had no effect on survival time in the ・winn勺rpeneutralization assay. 
The cytotoxic activities of immune and normal spleen cells used in this study were 30-40% and 
10-20%, respectively, at an E/T ratio of 20 : 1 inthe 5-hr 51Cr-release ass可， whereasthe cyto-
toxic activity of CTLL-D4 cells was approximately 50-60% at an E/T ratio of 2 : 1. In this 
experiment, the cytotoxic activity in vitro correlates well with an in vivo effect on survival. 
Howev巴r,the neutralizing effect of CTLL-D4 cells is not complete enough to cure the mice 
permanently, whereas the admixture of CTLL-D4 and RL古1injected intradermally could cure 
the mice peロnanently29l. Specific effects on the neutralization of the tumor were also studied 
(Table 1). Various tumor cells, RL舌6,RL♀9and EL-4, were inoculated together with CTLL-
D4 cells at an E/T ratio of 20 : 1. The effect on survival was only seen when CTLL-D4 cells 
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Fig. 2. Intracranial neutralization assay using cultured cel lines. CB6F 1・nu/nu
mice were injected with admixture of RL古land effector cels at various 
E/T ratios. Effector cels are CTLL-D4, E/T=20 : 1 (O), 10 : 1 （ム），
5 : 1 （口）， 1 : 1 (4),and D4f, E/T=20 1 （・）. Each group consisted of 
自veto五fteenmice. 
EXPERIMENTAL IMMUNOTHERAPY 
Table 1. Specific efect of CTL line on winn-type neutralization assay. 
Tumor叫 MSTbl土SD Number of mice rejected/tested 
RL古1 >60 7，円7
RL古6 14. 3±3.1 0/8 
RL古9 15.2土2.3 0/7 
EL-4 13. 2±2. 9 0/6 
•l CTLL-D4 cels (2×106) were admixed with various tumor cels 
(1×104). and then injected intracranially with a volume of 0.01 ml. 
。lMedian survival time in days. 
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cytotoxic effect of CTLL-D4 cells in vitro33> and that found in an in vivo subcutaneous neutrali-
zation assay29>. 
Adoptive Transfer of E貸ectorCells: In order to investigate the effector mechanisms 
in IC tumor rejection, various numbers of effector cells were adoptively transferred into CB6F1-
nu/nu mice which had been inoculated with 1×104 tumor cells intracranially 3 days earlier. 
To examine the dose of spleen cells that cured th巴mice(Table 2), the mice transplanted 
intracranially with 1×104 RL古1cells received different numbers of spleen cells. All the mice 
that had recieved more than 1×10s immune spleen cells were cured, whereas the mice that had 
received either normal spleen cells or less than l×10s immune spleen cells were not cured com-
pletely. The mice that had received more than l×10s immune spleen cells were resistant to an 
additional IC challenge of RL古1cells, and were cured permanently (data not shown). 
The specific effect of immune spleen cells on IC tumor rejection after intravenous transfer 
was also investigated (Table 3). The mice, which were transplanted intracrar山lywith the 
tumors, RL 6 1,RL 6 6, RL平9or EL・4,were treated with a single intravenous injection of 
l×108 RL 61-immune spleen cells. The results showed that only the mice inoculated with RL古1
Table 2. Dose response of spleen cels necessary to r句ectIC injected 
tumors in nude mice after IV transfer. 
Number of cels MSTbl土SD Number of mice transferred•> r吋ected/tested 
No transfer 15-3土1.2 0/10 
(Immune spleen) 
0.2x 108 17-6土2-4 0/9 
0.5x 108 19-8土3.5 7/1 
1.0x108 >60 12/12 
1.5×108 >60 10/10 
(Normal spleen) 
0.5× 10• 15-8土2-4 0/8 
1.0×108 16-1土2.1 0/9 
•l Various doses of CB6F1-nu／十 spleencels immunized against 
RL古1in vivo were intravenously transferred into CB6F1-nu/nu 
mice bearing 3-day RL古1(1×104) tumors. 
bJ Median survival time in day. 
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Table 3. Specific e仔ectof immune spleen cels on tumor rejection 
after IV transfer in nude mice•>. 
Tumorb> MST＜＞土SD Number of mice rejected/tested 
RL古1 >60 8/8 
RL古6 13.4±1.3 0/8 
RL早9 14.8土1.7 0/9 
EL-4 12.6士2.1 0/8 
•> Spleen cels of CB6F1-nu/+mice immunized against RL古1were 
used for efector cels at a dose of l×lQB. 
b) Various kinds of tumor cels (1×104) were intracranially injected 
in CB6F1-nu/nu mice 3 days before IV transfer of immune spleen 
cels. 
c) Median survival time in days. 
were cured. The adoptive transfer of RL古1-immunespleen cells had no effect on the growth of 
other tumor cels. 
Analysis of E貸ectorPopulations in Immune Spleen Cells: In order to clarify the 
effector population necessary to reject the tumor in an adoptive transfer study, immune spleen 
cells were treated before transfer into CB6F i-nu/nu mice (Table 4). The complement dependent 
cytotoxity test was carried out to eliminate desired effector subsets. The effect of immune spleen 
cells to cure the mice were totally eliminated by the treatment with anti Thy-1.2 Ab and C. The 
results indicated that Thy-1.2 positive cels, grossly identical with T cells, were necessary to reject 
the tumors. In the reciprocal experiment, the immune spleen cells were passed through a nylon-
wool column to enrich the non-B cells and non-adherent cells. This treatment had no effect on 
the capacity of immune spleen cells to cure the mice after adoptive transfer. The mice that 
received the spleen cells treated with anti Lyt-2.2 Ab and C were not cured, whereas two out of 
six mice that received spleen cells treated with anti Lyt-1.2 Ab and C were cured. Therefore, 
we can conclude that th巴 Thy-1.2positive T cells were necessary, and that especially Lyt-2 
positive cells play a major role in curing the mice with intracranially transplanted l戸nphoma.
The T-cell mediated tumor rejection was further examined in vivo. Either the cytotoxic 
Table 4. Efect of treatment of immune spleen cels on tumor rejection. 
Treatment•> MS Tb＞士SD Number of mice rejected/tested 
none >60 12/12 
anti Thy-l.2+C 15-8±1.5 0/10 
anti Lyt・l.2+C 24. 6±4. 8 2/6 
anti Lyt-2.2+ C 16.1土2.1 0/6 
NWP<> >60 8/8 
•> Treatment of immune spleen cels was performed before IV transfer 
(1×108) in nude mice bearing 3-day tumors. 
bJ Median survival time in days. 
c) Nylon wool passage (5×107). 
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Table 5. Efect of cel lines on tumor rejection after IV transfer. 
Effector cels3> Cel number MS Tb＞土SD Nu!llber of mic日e rejected/tested 
No cel transfer 15. 3±1. 2 0/10 
D4f 5×10' 14.3土2.5 0/8 
(noncytotoxic) l×10' 15.1土3.1 0/7 
CTLL-D4 2×10' 24. 4±5. 6 2/7 
(cytotoxic) 1×10' 19. 5±4. 7 0/6 
叫 E仔ectorcels were intravenously transferred into CB6F1-nude mice bearing 
3-day RL古1tumors. 
b) Median survival time in days. 
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cel line CTLL-D4 or noncytotoxic cel line D4f were transferred into the CB6F 1 nu/nu mice that 
had been inoculated with RL舌lintracranially 3 days earlier (Table 5). The CTLL-D4 cels 
mainly consisted of a Lyt-2+ cytotoxic population, whereas the D4f cels consisted entirely of 
Lyt-1+2-cels. Some mice were cured by the transfer of CTLL-D4 cels, but none were cured by 
transfer of nocytotoxic cels, D4f. These results indicate that Lyt・2+cytotoxic T cels play a 
major role in this type of tumor吋ection.
Discussion 
In the present study, two types of successful immunotherapy models, both local tumor 
neutralization and systemic transfer of effector cels, were demonstrated in IC tumor transplanted 
mice, and Lyt-2+ CTL populations were strongly suggested to play a major role in this type of 
tumor rejection. 
Numerous reports indicate that it is possible to obtain regression of established immnno-
genic murine or rats tumors by the passive transfer of T cells from tumor-immune donors2•6J. 
In most of these studies, however, immunotherapy had to be accompanied by chemotherapy7，叫39)
or by irradiation of the hostl9) in order to be successful, and the tumors used were invariably 
immunogenic to the host42,43,44>. These tumor systems, therefore, are only partially representative 
of the situation occurring in humans, since human tumors are only weakly or not immnnogenic1• 3>. 
The advancement in immunology has enabled us to use monoclonal antibodies32> and 
IL引 2>to investigate the details of an immune system, and to promote the clinical application of 
immunotherapy to malignanciess,21) Since the discovery of IL-2, the elucidation of the in vivo 
function of CTL and the establishment of an E伍cientimmunotherapeutic method were expected 
to follow because many CTL clones with different functions could be easily established and 
maintained11,12・4o,5o,52J. However, few studies have shown such IL・2-dependentclones to be 
effective on protecting against the allo-or syngeneic tumor growth in in vivo systemic transfer 
assaysu•52>. Several explanation for such in vivo ine伍ciencyof exogenous IL-2-dependent 
CTL clones or lines are possible: 1) CTL is not actually an effector subset19•21•34•35l, 2) the life 
span of such CTL clones are altered in vivo due to the extremely low level of TCGF13>, or the 
presence of an inhibitor to IL-226), 3) the loss of normal migration pattern caused by long-term 
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culture in IL-zio>, and 4) loss of specificity in the CTL clone49>. CTLL-D4 cels belong to an 
oligoclonal cel line, and consisted of a mixed population of Lyt-1 +23-, Lyt・1-23+and Lyt-1+23+, 
producing IL-2 in the culture supernatant stimulated with irradiated tumor cels in the presence 
of splenic feeder cels3). Although long-term culture of bulk ML TC cells without addition of 
TCGF has been considered to be impossible, we obtained CTLL-D4 cells by limiting dilution 
methods under 500 cells/well condition. This oligoclonal CTL line had in vivo e伍ciencybecause 
the addition of exogenous IL-2 is not necessaηr, and cell-cell interaction between helper T cels 
and cytotoxic T cells played a major role in in vivo tumor rejection29>. 
Recently, the importance of administration of IL-2 together with the CTL clone to enhance 
and maintain the cytotoxic activity has been stressed9·14•41>‘ However, experimental studies on 
immunotherapy have been carried out using subcutaneously or intraperitoneally transplanted 
tumor models, probably because of the peculiar immunological response in the central nervous 
systems (CNS)1>. The brain has been thought to be an“immunologically privileged site" 
because of its incapability of inducing allograft or even xenograft reactions36>. Recent ob-
servations, however, suggest that an immunological response can be built to intracranial tumors20, 
31•42•47>. We have already demonstrated the occurrence of immunological responses in the 
mouse brain, and concluded that the resistance in the brain against transplanted lymphomas is 
not essentially different from that in the peripheryso>. 
CTL generated in vitro has been shown to be effective against muτine tumors in a neutrali-
zation assay in the brain. RoMANI et al.43> reported that the intracerebral growth of a highly 
immunogenic murine lymphoma in an immunologically depressed host can be impaired by means 
oflocal adoptive immunotherapy. Systemic adoptive immunotherapy showed that CTL obtained 
from a secondary in vitro culture is as effective as that generated in a primary in vitro sensitization 
culture, whereas cultured normal lymphocytes or freshly harvested spleen cells have no thera-
peutic activity, the crucial points being the number of CTL injected and time of CTL admin 
istration 4>. 
SHIBUYA et al.48> reported on the systemic adoptive transfer of immunity by using glio-
sarcoma T9 cells in rat. Rejection of IC T9 challenge was obtained after transfer, in recipients 
of“hyperimmune”spleen cels, but was less (60% maximum) than that noted after ID challenge 
(100°/o). Their explanations for this difference were that: 1) IC tumor growth is more rapid 
than growth in ID site and is less rapidly inhibited, 2) immune cels, such as CTL, cannot reach 
the IC site in su伍cientnumbers as easily as they reach ID growing tumors, and 3) the brain is 
relatively deficient of antigen presenting cels. 
YA MASAKI et al. 52> succeeded in adoptive immunotherapy using tumor specific CTL clone 
for mouse malignant gliomas, and stressed the importance of dependency on dose and time of 
intravenous administration of CTL clone. They speculated that the increased intracranial pres-
sure due to the tumor growth could be a cause of the incomplete efficiency of adoptive immuno-
therapy. It is conceivable that the mice may not be cured because of the increased intracranial 
pressure due to the rapid growth of the tumor. Nevertheless an immune reaction 8trong enough 
ta regress the tumor can be produced in the CNS. 
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In our model using a radiation-induced l巴ukemiaRL 6 1, the intracranially-transplanted 
tumors killed the mice even when the mice were injected with only one thousand tumor cells 
(data not shown). In the Winn-type neutralization assay, as shown in Fig. 1 and Fig. 2, a few 
mice were not cured by the admixture of RL 61 cells with highly cytotoxic cells, CTLL-D4, 
although most of the mice survived for more than 60 days after mixed-inoculation, which is in 
contrast to the previous report that all the mice were cured by intradermal mixed-inoculation of 
CTLL-D4 cells and RL古1,even at the E/T ratio of 1 : 129>. This discrepancy might be due to: 
1) spread of injected cells to remote sites via the subarachnoid space, since the brain parench戸na
is easily damaged by mechanical injection, and 2) increased intracranial pressure due to the 
growth of tumoc cells. 
Thus, although many problems remain to be solved, the present study opens a new p巴r-
spective for therapeutic application Gf immunotherapy against brain tumor『．
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BALB/C .，，ウスに放射線で誘発された白血病細胞 RL♂1に特異的な細胞障害性を有し， かつT細胞増
RL♂1 を用い，（BALB/cXC57BL6)F1(CB6F1）マ 殖因子（IL-2）の添加なしで長期継代培養可能なLyt-2+
ウスを免疫して得たリンパ球を抗 Thy-1，抗 Lyt抗体 2＋より成るT細胞株を作製した．そして， あらかじ
と補体により処理し，CB6F,-nu/nu＂＜ ウスを recipi- め RL♂1を脳内lζ移植した CB6F1-nu/nuマウスに
entとして，腫蕩中和および移入試験をおこなった． 経静脈的に細胞株を移入したとζろ，抗腫蕩効果が確
その結果， Lyt-2+T細胞が移植同系腫湯の矩絶lζ必要 認された．
なエフェクター細胞である乙とが判明した．また，
